Business Context and Reporting Period
Company: Core Scientific, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 18, 2026 (Event Date); March 23, 2026 (Signature Date)
Context: The Company entered into a material definitive agreement to amend its existing credit facility, utilizing an accordion feature to increase term loan commitments.
Key Financial Metrics
- Debt Financing: Increased term loan commitments by $500.0 million.
- Total Commitment: The amended agreement brings total term loan commitments to $1.0 billion.
- Cash Flow Impact: The Company borrowed the full $500.0 million incremental commitment on the Closing Date (March 18, 2026).
- Lenders: JPMorgan Chase Bank, N.A. (Amendment No. 1 Term Lender) and Morgan Stanley Senior Funding, Inc. (Administrative/Collateral Agent).
- Revenue/Profit/Margins: The filing text does not provide a clear value for revenue, profit, cash flow from operations, or margins.
Material Changes
The primary material change is the expansion of the Company's debt capacity. Through Amendment No. 1 to the Delayed-Draw Bridge Credit Agreement, the Company increased its borrowing capacity by 50% relative to the prior commitment level (implied by the $500M increase to a $1.0B total). The full incremental amount was drawn immediately upon closing.
Guidance, Outlook, and Risks
- Management Commentary: The filing references a press release issued on March 23, 2026, regarding the amendment but does not include specific forward-looking guidance or operational outlook within the text provided.
- Risks and Contingencies: The filing notes the creation of a direct financial obligation. Specific terms, covenants, and interest rates are detailed in the Incremental Amendment (Exhibit 10.1) rather than the summary text.
- Unusual Items: None explicitly identified in the summary text beyond the significant debt drawdown.
Investor Verification Checklist
- Verify the specific interest rate, maturity date, and repayment terms of the new $500.0 million tranche in Exhibit 10.1.
- Review the amended financial covenants to assess the Company's compliance requirements under the new $1.0 billion total facility.
- Confirm the intended use of the $500.0 million proceeds as detailed in the March 23, 2026 press release (Exhibit 99.1).
- Assess the impact of the increased leverage on the Company's liquidity position and solvency ratios.